低剂量替西肽对无糖尿病成人肥胖患者血脂、葡萄糖稳态和肝脂肪变性指数的短期影响：一项前瞻性观察研究

IF 3.1 3区医学 Q3 ENDOCRINOLOGY & METABOLISM

Journal of diabetes and its complications Pub Date : 2025-10-09 DOI:10.1016/j.jdiacomp.2025.109181

Nikolaos Angelopoulos , Sarantis Livadas , Ioannis Androulakis , Valentina Petkova , Andreas Rizoulis , Anastasios Boniakos , Rodis Paparodis , Ploutarchos Tzoulis , Voula Mentzelopoulou , Dimos Florakis , Evangelos Fousteris , Areti Korakovouni , Dimitra Zianni , Zadalla Mouslech , Manfredi Rizzo , Dimitri P. Mikhailidis , Panagiotis Anagnostis

{"title":"低剂量替西肽对无糖尿病成人肥胖患者血脂、葡萄糖稳态和肝脂肪变性指数的短期影响：一项前瞻性观察研究","authors":"Nikolaos Angelopoulos , Sarantis Livadas , Ioannis Androulakis , Valentina Petkova , Andreas Rizoulis , Anastasios Boniakos , Rodis Paparodis , Ploutarchos Tzoulis , Voula Mentzelopoulou , Dimos Florakis , Evangelos Fousteris , Areti Korakovouni , Dimitra Zianni , Zadalla Mouslech , Manfredi Rizzo , Dimitri P. Mikhailidis , Panagiotis Anagnostis","doi":"10.1016/j.jdiacomp.2025.109181","DOIUrl":null,"url":null,"abstract":"<div><h3>Background/aims</h3><div>Tirzepatide has been approved for weight loss in adults with obesity. However, real-world data are still needed. This real-world prospective study is among the first to evaluate the short-term metabolic effects of low-dose tirzepatide in adults with obesity but without diabetes mellitus (DM). Secondary endpoints included associations between these changes and anthropometric or baseline metabolic parameters.</div></div><div><h3>Methods</h3><div>In this prospective observational study, adults with obesity but without diabetes mellitus received tirzepatide (2.5 mg/week, escalating to 5 mg/week, subcutaneously) for 12 weeks. Body weight, body mass index (BMI), total (TC), low-density (LDL-C) and high-density lipoprotein cholesterol (HDL-C), triglycerides, fasting plasma glucose (FPG), glycated hemoglobin (HbA1c), and hepatic steatosis index (HSI) were measured at baseline and week 12.</div></div><div><h3>Results</h3><div>Seventy-five participants (mean age 46.9 ± 9.9 years) were included. After 12 weeks, body weight (−8.1 ± 4.3 %) and BMI significantly decreased. TC, LDL-C, triglycerides, FPG, HbA1c, and HSI were significantly reduced and inversely associated with their baseline levels. HbA1c and HSI changes correlated with weight loss. No effect was observed on HDL-C. Statin use had no impact on outcomes.</div></div><div><h3>Conclusion</h3><div>Short-term low-dose tirzepatide improves the lipid profile, HbA1c, and HSI in obese adults without DM, especially in those with abnormal baseline values. Lipid changes occurred independently of weight loss.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 12","pages":"Article 109181"},"PeriodicalIF":3.1000,"publicationDate":"2025-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Short-term effects of low-dose tirzepatide on lipid profile, glucose homeostasis and hepatic steatosis index in adults with obesity, but without diabetes mellitus: a prospective observational study\",\"authors\":\"Nikolaos Angelopoulos , Sarantis Livadas , Ioannis Androulakis , Valentina Petkova , Andreas Rizoulis , Anastasios Boniakos , Rodis Paparodis , Ploutarchos Tzoulis , Voula Mentzelopoulou , Dimos Florakis , Evangelos Fousteris , Areti Korakovouni , Dimitra Zianni , Zadalla Mouslech , Manfredi Rizzo , Dimitri P. Mikhailidis , Panagiotis Anagnostis\",\"doi\":\"10.1016/j.jdiacomp.2025.109181\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background/aims</h3><div>Tirzepatide has been approved for weight loss in adults with obesity. However, real-world data are still needed. This real-world prospective study is among the first to evaluate the short-term metabolic effects of low-dose tirzepatide in adults with obesity but without diabetes mellitus (DM). Secondary endpoints included associations between these changes and anthropometric or baseline metabolic parameters.</div></div><div><h3>Methods</h3><div>In this prospective observational study, adults with obesity but without diabetes mellitus received tirzepatide (2.5 mg/week, escalating to 5 mg/week, subcutaneously) for 12 weeks. Body weight, body mass index (BMI), total (TC), low-density (LDL-C) and high-density lipoprotein cholesterol (HDL-C), triglycerides, fasting plasma glucose (FPG), glycated hemoglobin (HbA1c), and hepatic steatosis index (HSI) were measured at baseline and week 12.</div></div><div><h3>Results</h3><div>Seventy-five participants (mean age 46.9 ± 9.9 years) were included. After 12 weeks, body weight (−8.1 ± 4.3 %) and BMI significantly decreased. TC, LDL-C, triglycerides, FPG, HbA1c, and HSI were significantly reduced and inversely associated with their baseline levels. HbA1c and HSI changes correlated with weight loss. No effect was observed on HDL-C. Statin use had no impact on outcomes.</div></div><div><h3>Conclusion</h3><div>Short-term low-dose tirzepatide improves the lipid profile, HbA1c, and HSI in obese adults without DM, especially in those with abnormal baseline values. Lipid changes occurred independently of weight loss.</div></div>\",\"PeriodicalId\":15659,\"journal\":{\"name\":\"Journal of diabetes and its complications\",\"volume\":\"39 12\",\"pages\":\"Article 109181\"},\"PeriodicalIF\":3.1000,\"publicationDate\":\"2025-10-09\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of diabetes and its complications\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S105687272500234X\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"ENDOCRINOLOGY & METABOLISM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of diabetes and its complications","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S105687272500234X","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

摘要

背景/目的：stirzepatide已被批准用于成人肥胖患者的减肥。然而，仍然需要真实世界的数据。这项现实世界的前瞻性研究是首次评估低剂量替西帕肽对肥胖但无糖尿病（DM）的成人的短期代谢影响的研究之一。次要终点包括这些变化与人体测量或基线代谢参数之间的关联。方法在这项前瞻性观察性研究中，肥胖但无糖尿病的成年人接受替西帕肽（2.5 mg/周，逐渐增加到5 mg/周，皮下注射）治疗12周。在基线和第12周测量体重、体重指数（BMI）、总（TC）、低密度（LDL-C）和高密度脂蛋白胆固醇（HDL-C）、甘油三酯、空腹血糖（FPG）、糖化血红蛋白（HbA1c）和肝脂肪变性指数（HSI）。结果纳入75例，平均年龄46.9±9.9岁。12周后，体重（- 8.1±4.3%）和BMI均显著下降。TC、LDL-C、甘油三酯、FPG、HbA1c和HSI均显著降低，且与基线水平呈负相关。HbA1c和HSI变化与体重减轻相关。对HDL-C没有影响。他汀类药物的使用对结果没有影响。结论短期低剂量替西帕肽可改善无糖尿病的肥胖成人的血脂、HbA1c和HSI，尤其是基线值异常的肥胖者。脂质变化与体重减轻无关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Short-term effects of low-dose tirzepatide on lipid profile, glucose homeostasis and hepatic steatosis index in adults with obesity, but without diabetes mellitus: a prospective observational study

Background/aims

Tirzepatide has been approved for weight loss in adults with obesity. However, real-world data are still needed. This real-world prospective study is among the first to evaluate the short-term metabolic effects of low-dose tirzepatide in adults with obesity but without diabetes mellitus (DM). Secondary endpoints included associations between these changes and anthropometric or baseline metabolic parameters.

Methods

In this prospective observational study, adults with obesity but without diabetes mellitus received tirzepatide (2.5 mg/week, escalating to 5 mg/week, subcutaneously) for 12 weeks. Body weight, body mass index (BMI), total (TC), low-density (LDL-C) and high-density lipoprotein cholesterol (HDL-C), triglycerides, fasting plasma glucose (FPG), glycated hemoglobin (HbA1c), and hepatic steatosis index (HSI) were measured at baseline and week 12.

Results

Seventy-five participants (mean age 46.9 ± 9.9 years) were included. After 12 weeks, body weight (−8.1 ± 4.3 %) and BMI significantly decreased. TC, LDL-C, triglycerides, FPG, HbA1c, and HSI were significantly reduced and inversely associated with their baseline levels. HbA1c and HSI changes correlated with weight loss. No effect was observed on HDL-C. Statin use had no impact on outcomes.

Conclusion

Short-term low-dose tirzepatide improves the lipid profile, HbA1c, and HSI in obese adults without DM, especially in those with abnormal baseline values. Lipid changes occurred independently of weight loss.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Journal of diabetes and its complications 医学-内分泌学与代谢

CiteScore

5.90

自引率

3.30%

发文量

153

审稿时长

16 days

期刊介绍： Journal of Diabetes and Its Complications (JDC) is a journal for health care practitioners and researchers, that publishes original research about the pathogenesis, diagnosis and management of diabetes mellitus and its complications. JDC also publishes articles on physiological and molecular aspects of glucose homeostasis. The primary purpose of JDC is to act as a source of information usable by diabetes practitioners and researchers to increase their knowledge about mechanisms of diabetes and complications development, and promote better management of people with diabetes who are at risk for those complications. Manuscripts submitted to JDC can report any aspect of basic, translational or clinical research as well as epidemiology. Topics can range broadly from early prediabetes to late-stage complicated diabetes. Topics relevant to basic/translational reports include pancreatic islet dysfunction and insulin resistance, altered adipose tissue function in diabetes, altered neuronal control of glucose homeostasis and mechanisms of drug action. Topics relevant to diabetic complications include diabetic retinopathy, neuropathy and nephropathy; peripheral vascular disease and coronary heart disease; gastrointestinal disorders, renal failure and impotence; and hypertension and hyperlipidemia.